Pinos Elisabet de los - Feb 1, 2024 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Julie Feder, as Attorney-in-Fact
Stock symbol
AURA
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/2/2024, 04:01 PM
Previous filing
Jan 24, 2024
Next filing
Oct 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Award $0 +163K +100.93% $0.00 324K Feb 1, 2024 Direct F1
holding AURA Common Stock 131K Feb 1, 2024 By EdIP Revocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURA Stock Option (Right to Buy) Award $0 +237K $0.00 237K Feb 1, 2024 Common Stock 237K $7.77 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2025, subject to the Reporting Person's continued service as of each such vesting date.
F2 The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.
F3 The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

President and Chief Executive Officer